Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hildegund C J Ertl

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 3, 2011
The ideal vaccine: until death do us partHildegund C J Ertl
Frontiers in Immunology|April 30, 2021
T Cell-Mediated Immune Responses to AAV and AAV VectorsHildegund C J Ertl
Expert Opinion on Biological Therapy|July 2, 2003
Rabies DNA vaccines for protection and therapeutic treatmentHildegund C J Ertl
Frontiers in Immunology|August 29, 2022
Immunogenicity and toxicity of AAV gene therapyHildegund C J Ertl
Plos Neglected Tropical Diseases|September 30, 2009
Novel vaccines to human rabiesHildegund C J Ertl
Drugs|January 30, 2023
Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and ImmunosuppressionHildegund C J Ertl
Human Gene Therapy|October 20, 2023
Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus VectorsHildegund C J Ertl
Current Opinion in Molecular Therapeutics|February 25, 2003
Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/TherionHildegund C J Ertl
Virus Research|May 18, 2005
Immunological insights from genetic vaccinesHildegund C J Ertl
Vaccines|June 23, 2019
New Rabies Vaccines for Use in HumansHildegund C J Ertl
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 3, 2011
The ideal vaccine: until death do us partHildegund C J Ertl
Frontiers in Immunology|April 30, 2021
T Cell-Mediated Immune Responses to AAV and AAV VectorsHildegund C J Ertl
Expert Opinion on Biological Therapy|July 2, 2003
Rabies DNA vaccines for protection and therapeutic treatmentHildegund C J Ertl
Frontiers in Immunology|August 29, 2022
Immunogenicity and toxicity of AAV gene therapyHildegund C J Ertl
Plos Neglected Tropical Diseases|September 30, 2009
Novel vaccines to human rabiesHildegund C J Ertl
Drugs|January 30, 2023
Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and ImmunosuppressionHildegund C J Ertl
Human Gene Therapy|October 20, 2023
Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus VectorsHildegund C J Ertl
Current Opinion in Molecular Therapeutics|February 25, 2003
Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/TherionHildegund C J Ertl
Virus Research|May 18, 2005
Immunological insights from genetic vaccinesHildegund C J Ertl
Vaccines|June 23, 2019
New Rabies Vaccines for Use in HumansHildegund C J Ertl
Pageof 14